Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific conferences – the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, taking place on May 7-11, 2024, in Baltimore, Maryland, and the Protein Engineering Summit (PEGS) Boston Summit 2024, taking place on M